Personalized medicine using functional platelet tests and pharmacogenomic analyses may optimize the benefit-risk ratio of anti-platelet therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ivandic et al. (2010) conducted a review in Cardiovascular disease requiring anti-platelet therapy. Platelet function testing and pharmacogenomic analyses was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: